Guggenheim Boosts Axsome Therapeutics (NASDAQ:AXSM) Price Ta

Axsome Therapeutics (NASDAQ:AXSM – Get Rating) had its price objective upped by Guggenheim from $90.00 to $100.00 in a research report sent to investors on Tuesday morning, The Fly reports. AXSM has been the topic of a number of other research reports. StockNews.com began coverage on Axsome Therapeutics in a research report on Thursday, March […]

Related Keywords

China , United States , America , , China Universal Asset Management Co , Axsome Therapeutics Company Profile , Axsome Therapeutics Inc , Tower Research Capital , Armstrong Advisory Group Inc , Morgan Stanley , Axsome Therapeutics , Get Rating , Moderate Buy , Financial Advisors , Advisory Group , Universal Asset Management , Research Capital , Dark Forest Capital Management , Products Overview , Pipeline Overview , Axsome Therapeutics Daily , Nasdaq Axsm , Axsm , Medical , Boost Price Target , Guggenheim ,